Tags : Novo Nordisk

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives European Commission

Shots: The approval is based on results from pre-registration clinical programme assessing Esperoct in 270 patients with severe hemophilia A with 5+years of clinical exposure. The authorization covers all 28 European Union member states The marketing authorization follows EMA’s CHMP positive opinion granted on Apr 26, 2019 with its expected launch in European countries in […]Read More

Insights+: An Analysis of Biopharma Companies Growth in Last 20

In the last 20 years the global Biopharma space has changed a lot with ups and downs of companies and their growth. This analysis has found the multiple acquisitions and mergers along with the launch of several blockbusters leading to jump in growth and revenue of numerous companies. Pfizer acquired Warner-Lambert in 2000 to gain […]Read More

Top 20 BioPharma Companies based on 2018 Total Revenue

Top 20 BioPharma Companies based on 2018 Total Revenue The global pharma companies have been advancing their pipelines with emerging needs of patients. Pharma companies are also focusing on diagnostics & devices, which were emerged as one of major revenue generator in 2018, with the development of new products and devices. The year 2018 also […]Read More

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive

Shots: The positive opinion is based on largest pre-registration clinical programme assessing Esperoct (FD, IV, q4days) in 270 patients previously treated with severe hemophilia A and more than 5 years of clinical exposure   The study resulted in effective routine prophylaxis in people with severe hemophilia A, efficacious in treatment and control of bleeding episodes […]Read More

Novo Nordisk Files MAA for Semaglutide to the EMA for

Shots: The submission is based on 10 PIONEER studies assessing semaglutide vs sitagliptin, empagliflozin, liraglutide and dulaglutide in 9,543 adult patients with type 2 diabetes The collective studies result demonstrated reduction in HbA1c and weight loss with safe & well tolerated data Semaglutide (qd) is an oral GLP-1 receptor agonist administered once-daily with its expected […]Read More

Gilead and Novo Nordisk Collaborate to Conduct a Combination Therapy

Shots: Gilead collaborates with Novo for the onset of a clinical trial combining its Firsocostat and Cilofexor with Novo’s Semaglutide for the treatment of patients with Nonalcoholic Steatohepatitis (NASH) The focus of the collaboration is to combine Gilead and Novo’s expertise for the enhancement of research capabilities and approaches developing novel therapies in NASH Semaglutide […]Read More

Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its

Shots: The companies entered into an agreement to assess insulin dose data from Novo Nordisk’ pre-filled insulin pen connected to the digital health tool marked with Abbott’s FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system) The focus of an agreement is to advance management techniques for diabetes with the combination of the […]Read More

Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol,

Shots: The BLA approval is based on the trial assessing Esperoct (turoctocog alfa pegol, N8-GP) in 270 patients with previously treated people (PTPs) with severe haemophilia A The study resulted in maintanince of low median ABR of 1.18, efficacious in treatment & control of bleeding episodes, perioperative management and was well tolerated with no safety […]Read More